Vascular endothelial growth factor and breast cancer risk |
| |
Authors: | Katherine W Reeves Roberta B Ness Roslyn A Stone Joel L Weissfeld Victor G Vogel Robert W Powers Francesmary Modugno Jane A Cauley |
| |
Institution: | (1) Department of Public Health, School of Public Health and Health Sciences, University of Massachusetts, Amherst, 410 Arnold House, 715 North Pleasant Street, Amherst, MA 01003, USA;(2) Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA;(3) Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA;(4) University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;(5) Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA;(6) Department of Obstetrics &; Gynecology and Reproductive Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA;(7) Magee-Womens Research Institute, Pittsburgh, PA, USA |
| |
Abstract: | Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis and is important to carcinogenesis. Previous studies
relating circulating levels of VEGF to breast cancer have been limited by small numbers of participants and lack of adjustment
for confounders. We studied the association between serum VEGF and breast cancer in an unmatched case–control study of 407
pre- and postmenopausal women (n = 203 cases, n = 204 controls). Logistic regression was used to model the breast cancer risk as a function of natural log transformed VEGF
levels adjusted for age, Gail score, education, physical activity, history of breastfeeding, serum testosterone, and hormone
therapy (HT) use. The majority of the population was postmenopausal (67.6%) and the average age was 56 years; age and menopausal
status were similar among cases and controls. Geometric mean VEGF levels were non-significantly higher in cases (321.4 pg/ml)
than controls (291.4 pg/ml; p = 0.21). In a multivariable model, the odds of breast cancer was 37% higher for women with VEGF levels ≥314.2 pg/ml compared
to those with levels below 314.2 pg/ml, albeit not significantly (p = 0.16). There was no interaction between VEGF and menopausal status (p = 0.52). In this case–control study, VEGF was not significantly associated with breast cancer risk in pre- and postmenopausal
women. |
| |
Keywords: | Angiogenesis Breast neoplasms Premenopausal Postmenopausal |
本文献已被 PubMed SpringerLink 等数据库收录! |
|